SONIC HEALTHCARE

19 November 2026

The Manager – Listings
Australian Securities Exchange Limited
39 Martin Place
SYDNEY NSW 2000

Via electronic lodgement

Dear Sir / Madam

2026 ANNUAL GENERAL MEETING - CEO PRESENTATION AND PROXY VOTING SUMMARY

Dr Jim Newcombe, Chief Executive Officer, will present the attached slides at Sonic Healthcare's (ASX: SHL ; ADR: SKHHY) 2026 AGM today.

Confirmation of the Company's earnings guidance for FY2027 and related updates are included on slide 33 and 34.

The release of this announcement was authorised by the Board of Sonic Healthcare Limited.

Yours faithfully
Sonic Healthcare Limited

Paul Alexander
Company Secretary

Level 22, Grosvenor Place, 225 George Street, Sydney NSW 2000, Australia
T +61 2 9855 5444 | **F** +61 2 9878 5066 | **E** contactus@sonichealthcare.com.au
Sonic Healthcare Limited ABN 24 004 196 909
www.sonichealthcare.com

SONIC HEALTHCARE

Annual General Meeting

19 November 2026

Summary of direct and proxy votes received before the AGM

	RESOLUTION	FOR	AGAINST	OPEN	ABSTAIN
1	Professor Mark Compton Re-election as Director	267,003,647 (91.51%)	23,754,564 (8.14%)	1,022,139	138,121
2	Mr Neville Mitchell Re-election as Director	277,698,266 (95.18%)	13,035,950 (4.47%)	1,028,140	156,115
3	Professor Suzanne Crowe Re-election as Director	274,060,826 (93.92%)	16,720,716 (5.73%)	1,012,792	124,137
4	Mr Chris Wilks Re-election as Director	287,028,572 (98.38%)	3,710,907 (1.27%)	1,027,502	151,490
5	Adoption of Remuneration Report	261,098,053 (89.80%)	28,691,323 (9.87%)	967,543	596,495
6	Approval of issue of securities under Employee Option Plan as an exception to ASX Listing Rule 7.1	181,006,613 (62.16%)	109,235,562 (37.51%)	978,513	132,726
7	Approval of issue of securities under Performance Rights Plan as an exception to ASX Listing Rule 7.1	178,657,192 (61.34%)	111,619,112 (38.33%)	964,562	112,548
8	Approval of long term incentives for Dr Jim Newcombe	278,328,683 (95.60%)	11,848,435 (4.07%)	966,380	209,916
9	Approval of long term incentives for Mr Chris Wilks	278,338,313 (95.60%)	11,835,090 (4.07%)	976,313	203,698
10	Renewal of Proportional Takeover Bid Approval Provisions	290,120,942 (99.48%)	489,531 (0.17%)	1,032,751	275,247

SONIC HEALTHCARE

CEO Presentation

Dr Jim Newcombe

Annual General Meeting

19 November 2026

Disclaimer

Forward Looking Statements

This presentation may include forward-looking statements about Sonic Healthcare's financial results, guidance, business prospects and other future matters that may involve risks and uncertainties, many of which are outside the control of Sonic Healthcare. Forward-looking statements can generally be identified by the use of words such as "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "believe", "forecast", "estimate", "target", "outlook", "guidance" and other similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and reflect management's current estimates, projections, expectations or beliefs. Forward-looking statements are based on assumptions and contingencies that are subject to change without notice and involve known and unknown risks, uncertainties and other factors that could cause actual results, performance and outcomes to be materially different from those expressed, anticipated or implied by those statements.

Risks and uncertainties that may affect the future results of the company include, but are not limited to, adverse decisions by governments and healthcare regulators, changes in the competitive environment and billing policies, lawsuits, loss of contracts, unexpected growth in costs and expenses, changes in macroeconomic conditions, foreign exchange rates and capital market conditions, and additional risks and uncertainties not presently known to management or not currently considered material. The statements being made in this presentation do not constitute an offer to sell, or solicitation of an offer to buy, any securities of Sonic Healthcare, nor do they constitute financial product, investment, legal, tax, accounting or other advice or a recommendation to acquire Sonic Healthcare securities. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person, including Sonic Healthcare. In particular, no representation, warranty or assurance (express or implied) is given in relation to any underlying assumption or that any forward-looking statement will be achieved.

Actual future events, results and outcomes may vary materially from the forward-looking statements and the assumptions on which the forward-looking statements are based. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. To the maximum extent permitted by law, Sonic Healthcare and its directors, officers, employees, agents and advisers disclaim any liability for any loss arising from use of, or reliance on, any forward-looking statement or other information in this presentation. Except as required by law or regulation, including the ASX Listing Rules, Sonic Healthcare undertakes no obligation to update, revise or supplement any forward-looking statement, whether as a result of new information, future events, results or otherwise. The information provided in this presentation is based on and should be read in conjunction with Sonic Healthcare's FY2026 Annual Report and other periodic and continuous disclosure announcements lodged with the ASX.

Non-IFRS Information

This presentation includes certain financial measures presented on an "underlying" and/or "constant currency" basis, which are not prepared in accordance with International Financial Reporting Standards (IFRS). These measures are used by management to assess the underlying performance of the business and should be considered in addition to, and not as a substitute for, financial information prepared in accordance with IFRS. Non-IFRS financial measures may not be directly comparable with similarly titled measures presented by other entities. A reconciliation of the underlying financial measures to the corresponding measures reported in accordance with IFRS is provided within the company's FY2026 Annual Report.

Insights from the past year



Bioscientia, Germany, December 2025

Insights from the past year

1 Strong foundations

Sonic Healthcare's global platform and competitive differentiators provide strong foundations for long-term, sustained growth

Scale and diversification




Sonic Healthcare is one of the world's leading medical diagnostics companies


#1
in 6 markets

9 Countries	**11** Markets	**144m** FY2026 Patient Consultations	**3,200** Patient Access Points
343 Laboratories	**47,658** Our People	**2,400** Pathologists, Radiologists & other clinicians	**$10.9b** FY2026 Revenue

Medical Leadership value cycle



Operational excellence



Sonic Healthcare's investment proposition

We deliver high-value medicine at scale, driving growth and financial performance

Insights from the past year

2 Significant opportunities ahead

Industry trends and untapped potential within Sonic Healthcare create opportunities for growth and improved returns

Leveraging our strengths to accelerate growth

Industry Trends	Sonic Healthcare's Competitive Advantages
Growing demand for healthcare services Ageing populations, new tests and increasing consumer needs **Pressure on healthcare payor budgets** As demand for healthcare services grows	Leading market positions and high-volume, efficient operations Geographically diversified and expanding revenue streams outside core payor channels
Increasing chronic and complex disease Higher testing intensity and complexity	Deep expertise in advanced diagnostics and specialist testing
Growing demand for personalised medicine Emphasising the value of trusted patient and doctor relationships	Medically-led, patient-centred care delivered through trusted brands

Federation 2.0 – optimising our federated structure will create greater financial value

Federated Strengths

- Trusted local branding
- Strong customer relationships
- Deep local market knowledge
- Entrepreneurship and innovation

Global Opportunities

- Addressing new markets with proven strategies
- Sharing knowledge and scaling innovation
- Building enterprise-wide digital infrastructure
- Optimising shared services delivery

Financial Value

Strong, sustained revenue growth

High-value, diversified revenue growth by sharing and scaling innovation, expertise and proven strategies

Lower structural cost base

Increasing scale efficiencies and reducing duplication

Insights from the past year

3 Clear alignment on financial outcomes

Focus on EPS and ROIC growth in decision-making will drive shareholder value

Disciplined execution to drive shareholder value

Comprehensive internal alignment on key financial outcomes

- Expanded performance-based remuneration structures
- Rigorous investment assessment
- Robust business case analysis
- Refined global project management framework

Core metrics – EPS and ROIC

FY2026 financial results demonstrated early progress, while initiatives commenced during the year lay the groundwork for further improvement in earnings and returns

FY2026 review

Solid financial results with EBITDA guidance achieved

REVENUE

$10,867m

▲13% year-on-year

ORGANIC REVENUE GROWTH

5%

Track record of strong growth

EBITDA

$1,933m

▲11% year-on-year

NET PROFIT

$621m

▲17% year-on-year

EARNINGS PER SHARE

125.6c

▲14% year-on-year

ROIC

6.5%

▲+60bps year-on-year

Note: All financial numbers are on an underlying basis unless otherwise stated

Strong execution across key initiatives

Acquisition synergy realisation on track

LADR (Germany): >40% of total expected synergies achieved in first year following this major acquisition

Synlab Suisse & Dr Risch Group (Switzerland): strong incremental profit realised, further strengthening our market position

Key growth initiatives outperforming

Advanced diagnostics: double-digit organic growth across Sonic Genetics (Australia), Biovis (Germany) and US division, including Cairo Diagnostics

Direct-to-consumer testing: >60% growth in Mein Direktlabor (Germany), leveraging our existing lab infrastructure

US operating review delivering benefits

Cost reduction initiatives, including: nine anatomical pathology practices rationalised; further procurement savings secured and 10% support function headcount reduction initiated

Organic growth initiatives, including: advanced diagnostics expansion and nationwide sales optimisation

Investment-grade balance sheet

Credit Metrics		30 June 2026	30 June 2025
Net interest-bearing debt	A$m	3,069	2,818
Equity	A$m	8,493	8,473
Debt cover	X	2.2	2.1
Gearing ratio	%	25.9	24.7
Interest cover	X	10.0	10.1

- Increase in net debt largely relates to acquisitions of LADR and Cairo Diagnostics, partially offset by proceeds of sale and leaseback

Progressive dividend maintained

A$	FY2026	FY2025	Growth
Interim Dividend	$0.45	$0.44	2.3%
Final Dividend	$0.63	$0.63	0%
Total Dividends	$1.08	$1.07	0.9%

- Dividend franked to 60%
- Expect future earnings growth to support achievement of the target dividend payout ratio (70-80% of net profit)

Capital management – property transactions



Sale and Leaseback Completed

Bowen Hills, Brisbane

- Completed sale and leaseback to Charter Hall for a purchase price of $445m
- Released capital invested at a pre-tax return of ~5.6%
- Unlocked value not reflected on the financial statements



Conditional Contract Signed

95 Epping Rd, Macquarie Park, Sydney

- Sale of surplus property
- Contract signed with settlement conditional on DA
- Settlement expected late CY2027
- Expected pre-tax profit ~$50m

Global digital and AI transformation

Commenced strategic initiatives in FY2026 to modernise Sonic Healthcare's global digital infrastructure, improving productivity and creating a foundation for responsible use of AI



Back Office

Modernising finance, supply chain and HR systems to leverage scale and drive efficiencies, including through deployment of AI (project initiated in FY2026, with ~A$30m investment per annum for the next 3 years)



Operational

Optimising laboratory and radiology workflows, including proprietary Laboratory Information Systems and Radiology Information System



Clinical

Scaling leading-edge digital and AI applications in pathology and radiology, including proprietary patient and doctor apps

Strengthening leadership structures and roles

New Leadership Structures

Sonic Healthcare Germany

11 federation members combined into three operating divisions to accelerate synergy capture and efficiencies, overseen by a five-person executive management team



Sonic Healthcare Australia

Increased collaboration across pathology, radiology, clinical services and support functions to strengthen the combined offering and unlock opportunities and efficiencies



New Global Leadership Roles

Chief Digital, Data and Information Officer

Matthias Hansen



Chief People Officer

Graham Beal



Sustainability

Sustainability Impact Report and ESG ratings



sonichealthcare.com/sustainability

ISS ESG
Prime (B-)

FTSE4Good
FTSE4Good All World Index
FTSE4Good Developed Index

MSCI
Leader (AA)

CDP
Awareness (C)

MORNINGSTAR SUSTAINALYTICS
16.8 - Low Risk

Sustainability highlights

ENVIRONMENT

10%
Reduction in scope 2 market-based emissions against restated prior year

41%
Hybrid or electric motor vehicles in global fleet

27%
Increase in global electricity generated by on-site solar installations

44%
Global electricity from renewable sources

OUR PEOPLE

99%
Staff access to an employee assistance program

39%
Women in executive senior leadership positions

COMMUNITIES

144 million
Patient consultations

100%
Facilities quality accredited in FY2026

GOVERNANCE

✓
Continued improvement of cybersecurity posture using NIST CSF Version 2.0



Published Modern Slavery Statement 2026

Sonic Healthcare Foundation

Improving the health and wellbeing of communities around the world through healthcare infrastructure, diagnostics, training and preventative care

30 years in Africa

The opening of Sonic Kworo Hospital in north Uganda represents the most significant undertaking in the Foundation's history



New 42-bed maternal health facility opened in Uganda, providing maternal and paediatric care at no cost to patients



Baby Barbara was the hospital's first newborn



Global Leaders Summit 2026

Global Leaders Summit

Leaders from across Sonic Healthcare



Strategies to grow shareholder value

Grow and diversify revenue

Broaden the customer base with enhanced digital access and new channels

Expand personalised and precision medicine, including advanced diagnostics

Deliver high-quality care at higher margins

Scale automation, robotics and AI to grow capacity and reduce cost

Optimise the Federation to capture more value from global scale and expertise

Expand personalised and precision medicine

Leveraging Sonic Healthcare's strengths in advanced diagnostics




Women's Health

- Prenatal care and maternal-fetal medicine, e.g. NIPT, expanded carrier screening, parental karyotyping
- Cervical screening including comprehensive HPV genotyping
- Gynaecological oncology, e.g. BRCA1/2, tumour molecular profiling



Neurology

- Alzheimer's disease biomarkers
- Concussion biomarker testing
- PET-CT for dementia diagnosis
- Functional MRI and angiography



Mental Health

- Pharmacogenomics (Sonic PGx Panel), including personalised guidance for:
  - ADHD medications
  - Antidepressants
  - Antipsychotics



Longevity

- Biological age testing
- Microbiome analysis
- Chronic disease risk profiles
- Mitochondrial function panels

FY2027 outlook

FY2027 guidance update

EBITDA guidance reaffirmed after four months' trading

- EBITDA A$1,950 – A$2,030 million (constant currency), excluding back-office IT systems transformation costs of ~A$30 million

Other guidance

- Depreciation expense (including on leased assets) was forecast to be A$810 – A$825 million (constant currency), now tracking to lower half of the range (excluding any further sale and leaseback of properties)
- Amortisation expense was forecast to be A$90 – A$95 million (constant currency), now tracking to lower half of the range
- Interest expense now expected to increase by ~8% (constant currency) versus prior year, increase from previous guidance due to base rate rises
- Effective tax rate ~27%

Key guidance considerations

- Excludes any gains from sale of properties
- Includes completed acquisitions only
- No future regulatory changes assumed (including PAMA)
- Assumes current interest rates prevail

FY2027 updates

- Organic revenue growth YTD October (constant currency) in line with expectation at 4.4%[1]
- Strong organic growth rates in major markets
- Continued momentum in key growth areas, including advanced diagnostics, direct-to-consumer testing and specialist referrals
- Achieving margin expansion as expected
- German and Swiss synergy realisation ongoing as planned
- US operating review ongoing, specific initiatives tracking to plan
- Potential PAMA impact for FY2027 updated to ~A$24m, based on recent draft CMS fee schedule, remains uncertain that changes will occur
- New conditional contract to provide pathology services for Mater hospitals in Brisbane

Organic revenue growth for key markets YTD October 2026[1]

Germany	4%
Australian Pathology	6%
USA	4%
Switzerland	1%[2]
UK	4%
Radiology	8%
SCS	5%

1. Per working day
2. Includes the ~(3)% impact of fee changes effective 1 July 2026

Key takeaways

Sonic Healthcare has strong foundations and significant untapped potential. Our focus is on converting that potential into stronger earnings, improved returns and long-term shareholder value.

Deliver on the operational and financial initiatives underway

Optimise our federated structure to drive greater financial value

Pursue growth opportunities with medical and financial discipline

Sonic Healthcare's global people

Caring for our communities



Thank you

SONIC HEALTHCARE

